Hong Kong has officially inaugurated the Centre for Medical Products Regulation (CMPR), a new body tasked with overseeing the approval and regulation of medical products in the city. Dr. Li Zili, the newly appointed controller of the CMPR, stated that the agency’s primary goal is to establish itself as a globally trusted authority.

Dr. Li emphasized that the CMPR intends to act as a catalyst for medical innovation. He explicitly noted that the agency does not aim to be a "miniature version" of regulatory bodies found in other jurisdictions. Instead, the CMPR plans to develop a regulatory framework tailored to Hong Kong’s specific needs, distinguishing it from established agencies in mainland China, Singapore, and Japan.

While the agency is in its early stages, the government’s move is seen as an effort to modernize the city’s healthcare infrastructure and improve its competitiveness in the global pharmaceutical market. The agency is expected to navigate the complexities of international standards while maintaining local oversight. Currently, the focus remains on building institutional trust and defining the specific operational scope of the new body as it begins its mandate.